CD8A and neoplasm: A recent study by Zhang et al. reported that treatment with anti-TIGIT mAbs 3 days after tumor cell implantation prevented tumor-infiltrating NK cell exhaustion in CT26 or methylcholanthrene (MCA)-induced fibrocarcinoma-bearing mice, which resulted in the enhancement of CD8+T cell responses and tumor rejection [34].